GBA Presents: RADIO SAVANT-!

stonedinvestor said:
One of the oldest tricks in investing is getting on board an accretive purchase-!

This is the upgrade that caught my eye on Oct 3>

DA Davidson upgrades Federal Signal to Buy, 'intrigued' by TowHaul deal 10/07 FSS DA Davidson analyst Michael Shlisky upgraded Federal Signal to Buy from Neutral with a price target of $46, up from $39, after hosting an Industrials conference and holding a follow-up call with its management. The analyst contends that owning a government-focused Machinery company in a recession remains appealing, and this time it is backed by large and already-passed stimulus bills. Shlisky adds that he was intrigued by management's comments about the TowHaul deal and the company's ability to maintain pricing when commodity prices revert, stating that its sources of upside from macro, end-market, and company-specific factors could drive increased investor attention.
More...
It's had its run Stoney.
It's a multi-nat dinosaur based out of friggin' Chicago.
FX is gonna kill their next earnings report.
They sell street-sweepers and septic pump trucks... it doesn't get any lower PE than that stuff. Lousy dividend too.
 
FROM NOW ON THIS IS THE SECRETE SIGNAL


ONLY ONE MAN WAS CORRECT<----

ONLY ONE MAN CALLED THE BOTTOM <------------

WHEN ALL OTHERS WERE SCARED AND 1 IN PARTICULAR PEED HIS PANTS ON NATIONAL TV

ONE MAN STEPPED UP.... AND ATE A GUMMY. FIXED THE FED & STOPPED THE MADNESS,,,

WHEN WILL JIMMY GET ON BOARD THE RALLY?

WHEN WILL OVERNIGHT ADMIT HIS FOLLY?
 
... also what i like about FSS is after the buy...


Federal Signal Announces New $800 Million Credit Facility
Mon, October 24, 2022, 8:00 AM
In this article:
  • FSS
    +3.64%


OAK BROOK, Ill.,Oct. 24, 2022/PRNewswire/ -- Federal Signal Corporation (NYSE: FSS) (the "Company"), a leader in environmental and safety solutions, announced the completion of a new five-year$800 millioncredit facility, to replace its existing$500 millioncredit facility. The new facility is comprised of a$675 millionrevolving credit facility and a$125 millionterm loan facility. The arrangement also provides the Company with the ability to further expand its borrowing capacity by up to the greater of (i)$400 millionand (ii) 100% of Consolidated EBITDA for the applicable four-quarter period preceding such expansion notice, subject to approval by applicable lenders.

Jennifer L. Sherman, Federal Signal's President and Chief Executive Officer, commented, "We are extremely pleased to announce this new credit facility, which provides greater financial flexibility to invest in internal growth initiatives and pursue additional acquisitions. The terms of the new facility are more favorable to the Company, reflecting our strong cash flow and balance sheet. This marks another important milestone for the Company, as we continue to execute on our strategic long-term growth objectives."

The syndication of the new facility was completed with Wells Fargo Securities, LLC, PNC Capital Markets LLC and Truist Securities, Inc. acting as Joint Lead Arrangers and Joint Bookrunners, PNC Bank, National Association and Truist Bank as Syndication Agents, and JPMorgan Chase Bank, N.A. and The Toronto Dominion Bank,New YorkBranch as Documentation Agents.
 
stonedinvestor said:
An opportunity in breasts?

B. Riley sees 'major tailwind' for Establishment Labs in 2023 07:47 ESTA, JNJ B. Riley analyst Neil Chatterji believes Establishment Labs' planned commercial launch of Motiva into the U.S. market will be a "major tailwind" in 2023, with the company positioned to take share with its "differentiated smooth and natural feel premium implants." The U.S. market is almost half the $1.5B global breast augmentation market, and 80% of the market is aesthetic procedures, Chatterji tells investors in a research note. Motiva should likely be well received by the U.S. plastic surgeon community upon expected approval and launch, particularly given its sub-1% complication rates historically over more than a decade versus much higher competitor rates, and its natural feel and look, says the analyst. He thinks Johnson & Johnson's (JNJ) Mentor unit and AbbVie's (ABBV) Allergan Aesthetics business unit are not a significant focus for either parent company with limited innovation investments, which makes it possible for Establishment to take share from both over time. Chatterji keeps a Buy rating on Establishment Labs with a $107 price target following yesterday's short report.

ESTA-$51.00 (don't see much reaction to short report though)
More...

--->>Yesterday's short report ... :rolleyes:

ONLY ONE MAN CALLED THE SHORT A YEAR AGO AT $84


vanzandt said:
ESTA goes in granny's shorts stoney.
$84.40
This thing will be in the $70's by mid-July
More...

:sneaky::cool::p
 
Futures are slightly Up I am out of here!

One thing i don't like about STOKE is it's about the eyes and for whatever reason the eyse have been a tricky place for me in Biotech. I had one huge score with Alergan but over the years many of these eye based bios have crapped out.

Much rather be in cancer game<--

As well I am having REAL serious issues with my own eyes don't tell my wife...
I'm not exactly a go to the Dr guy but...

Something has to give here so reading about various fatal eye conditions does not warm my heart.

TALK TO YOU AT 2:00 pm. ~si

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
1493579a52f274c4419bf6225c857ee6

August 25, 2022
In this article:
  • STOK
    +4.04%


– ADOA is primarily caused by mutations in the OPA1 gene that result in progressive and irreversible vision loss in both eyes starting in the first decade of life –

– The FALCON study is designed to evaluate disease progression and its effects on patients –

– Data will support clinical development plans for STK-002, a potential new medicine that targets the underlying cause of ADOA –
 
You must log in or register to reply here.
Back
Top